PRAX Share Price Performance
US$269.26
196.42 (269.66%)
214.0% overvalued intrinsic discount
US$85.76
Fair Value
Price US$269.26
AnalystLowTarget US$85.76
Fair ValueUS$85.76
Share Pricen/a
Praxis Precision Medicines, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
PRAX Community Narratives
AN
Fair Value US$85.76 214.0% overvalued intrinsic discount
Future Epilepsy Trial Costs And Financing Needs Will Pressure Long-Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Future Epilepsy Trial Costs And Financing Needs Will Pressure Long-Term Earnings Potential
Catalysts About Praxis Precision Medicines Praxis Precision Medicines is a clinical stage biotechnology company focused on developing targeted therapies for central nervous system disorders, with an emphasis on epilepsy and rare developmental epileptic encephalopathies. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$85.76
214.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
117.3% p.a.
Profit Margin
16.03%
Future PE
262.51x
Price in 2028
US$105.17
Trending Discussion
Recently Updated Narratives
AN
Future Epilepsy Trial Costs And Financing Needs Will Pressure Long-Term Earnings Potential
Fair Value: US$85.76 214.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Praxis Precision Medicines, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -10.92
- -3,194.88%
- -3,658.53%
- 0%
About PRAX
- Founded
- 2015
- Employees
- 116
- CEO
- WebsiteView website
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
